Saturday, March 15, 2025 | 06:27 PM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Cadila Healthcare receives US FDA approval for schizophrenia drug

The product will be manufactured at Liva Pharma's manufacturing facility at Vadodara

Cadila Healthcare, Moraiya

File photo of Cadila Healthcare's Moraiya facility

Press Trust of India New Delhi

Drug firm Cadila Healthcare on Thursday said it has received approval from the USFDA for Haloperidol Decanoate injection used in treatment of schizophrenia.

The product will be manufactured at Liva Pharma's manufacturing facility at Vadodara, Cadila Healthcare said in a BSE filing.

Haloperidol is used in the treatment of schizophrenia and for the control of tics and vocal utterances of Tourette syndrome.

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Oct 24 2019 | 11:40 AM IST

Explore News